The FDA has approved Bimzelx® (bimekizumab-bkzx) for the treatment of moderate to severe hidradenitis suppurativa in adults.

Work-time, rather than leisure-time or nonworkday, activity behavior seems to be associated with 24-hour ambulatory blood pressure.

Several adverse health outcomes are associated with AD, such as atopic and allergic conditions, immune mediated conditions, and more.

Treatment with dupilumab is safe and effective for patients with bullous pemphigoid, with complete remission seen as early as 4 weeks of treatment.

COVID-19, influenza, and RSV vaccination coverage is low among nursing home residents early in the 2024 to 2025 season.

Vaccination of 27- to 45-year-olds against HPV is less cost-effective than vaccination of younger persons (aged 9 to 26 years).

Poor control over specific aspects of work is associated with burnout among physicians, according to study findings.

Baricitinib is an effective treatment option for children and adolescents with atopic dermatitis, with no new safety signals identified.

Deucravacitinib outperformed placebo for treating moderate to severe scalp psoriasis, even among patients with less extensive overall disease.

Tumor characteristics differ significantly among pediatric and adolescent and young AYA patients with melanoma, with decreasing incidence rates seen among young patients with cutaneous melanoma.

Preterm infants have thicker superficial components and more stepped borders for infantile hemangioma when compared with term infants.

No new safety concerns were observed through 16 weeks among pediatric patients with juvenile psoriatic arthritis or enthesitis-related arthritis receiving ixekizumab. Ixekizumab (IXE) demonstrated ...